CA2978668A1 - Organic compounds - Google Patents
Organic compoundsInfo
- Publication number
- CA2978668A1 CA2978668A1 CA2978668A CA2978668A CA2978668A1 CA 2978668 A1 CA2978668 A1 CA 2978668A1 CA 2978668 A CA2978668 A CA 2978668A CA 2978668 A CA2978668 A CA 2978668A CA 2978668 A1 CA2978668 A1 CA 2978668A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- net
- sert
- disorder
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135915P | 2015-03-20 | 2015-03-20 | |
| US62/135,915 | 2015-03-20 | ||
| PCT/US2016/023198 WO2016154027A1 (en) | 2015-03-20 | 2016-03-18 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2978668A1 true CA2978668A1 (en) | 2016-09-29 |
Family
ID=56977765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2978668A Abandoned CA2978668A1 (en) | 2015-03-20 | 2016-03-18 | Organic compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10188758B2 (https=) |
| EP (1) | EP3270920B1 (https=) |
| JP (1) | JP6726200B2 (https=) |
| KR (1) | KR20170129906A (https=) |
| CN (1) | CN107405339A (https=) |
| AU (1) | AU2016235483A1 (https=) |
| BR (1) | BR112017020135A2 (https=) |
| CA (1) | CA2978668A1 (https=) |
| ES (1) | ES2819833T3 (https=) |
| IL (1) | IL254320A0 (https=) |
| MX (1) | MX2017012022A (https=) |
| RU (1) | RU2017134796A (https=) |
| WO (1) | WO2016154027A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3339304A1 (en) | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Quinoline and isoquinoline derivatives for treating pain and pain related conditions |
| EP3339307A1 (en) * | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions |
| JP2022506378A (ja) * | 2018-11-02 | 2022-01-17 | エステベ ファーマシューティカルズ，ソシエダッド アノニマ | 疼痛及び疼痛に関連する状態を処置するための新規なテトラヒドロピリミドジアゼピン及びテトラヒドロピリドジアゼピン化合物 |
| EP3873901A1 (en) * | 2018-11-02 | 2021-09-08 | Esteve Pharmaceuticals, S.A. | New alcoxyaminopyridine derivatives for treating pain and pain related conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ313076A (en) * | 1995-07-24 | 1999-11-29 | Lilly Co Eli | Medicament containing duloxetine for treating hyperactivity and attention deficiency disorders |
| EP1587781A1 (en) * | 2002-11-05 | 2005-10-26 | Eli Lilly And Company | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| BRPI0510453A (pt) * | 2004-04-30 | 2007-10-30 | Warner Lambert Co | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central |
| WO2007010082A1 (en) * | 2005-07-15 | 2007-01-25 | Fermion Oy | Process for preparing a 3-aryloxy-3-arylpropylamine |
| EP2066630A1 (en) * | 2006-08-23 | 2009-06-10 | Pfizer Products Incorporated | Piperidine derivatives |
| ES2553891T3 (es) * | 2007-06-04 | 2015-12-14 | Intra-Cellular Therapies, Inc. | Derivados de piridina como moduladores NET/SERT |
| WO2010120910A1 (en) * | 2009-04-15 | 2010-10-21 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| US9352218B2 (en) | 2009-04-21 | 2016-05-31 | Nintendo Co., Ltd. | Game apparatus and computer-readable storage medium |
-
2016
- 2016-03-18 US US15/560,107 patent/US10188758B2/en active Active
- 2016-03-18 BR BR112017020135A patent/BR112017020135A2/pt not_active Application Discontinuation
- 2016-03-18 WO PCT/US2016/023198 patent/WO2016154027A1/en not_active Ceased
- 2016-03-18 CN CN201680014968.7A patent/CN107405339A/zh active Pending
- 2016-03-18 CA CA2978668A patent/CA2978668A1/en not_active Abandoned
- 2016-03-18 EP EP16769428.0A patent/EP3270920B1/en active Active
- 2016-03-18 KR KR1020177030305A patent/KR20170129906A/ko not_active Withdrawn
- 2016-03-18 MX MX2017012022A patent/MX2017012022A/es unknown
- 2016-03-18 ES ES16769428T patent/ES2819833T3/es active Active
- 2016-03-18 AU AU2016235483A patent/AU2016235483A1/en not_active Abandoned
- 2016-03-18 RU RU2017134796A patent/RU2017134796A/ru not_active Application Discontinuation
- 2016-03-18 JP JP2017549188A patent/JP6726200B2/ja active Active
-
2017
- 2017-09-04 IL IL254320A patent/IL254320A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107405339A (zh) | 2017-11-28 |
| ES2819833T3 (es) | 2021-04-19 |
| US10188758B2 (en) | 2019-01-29 |
| BR112017020135A2 (pt) | 2018-05-29 |
| EP3270920B1 (en) | 2020-06-17 |
| RU2017134796A (ru) | 2019-04-04 |
| EP3270920A4 (en) | 2018-10-24 |
| JP2018508556A (ja) | 2018-03-29 |
| MX2017012022A (es) | 2018-01-30 |
| WO2016154027A1 (en) | 2016-09-29 |
| JP6726200B2 (ja) | 2020-07-22 |
| AU2016235483A1 (en) | 2017-10-12 |
| IL254320A0 (en) | 2017-11-30 |
| EP3270920A1 (en) | 2018-01-24 |
| KR20170129906A (ko) | 2017-11-27 |
| US20180099060A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6964450B2 (ja) | 造影剤の合成および使用のための組成物、方法およびシステム | |
| US8710086B2 (en) | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof | |
| EP3630757A1 (en) | Novel deuterium substituted positron emission tomography (pet) imaging agents and their pharmacological application | |
| JPH05501540A (ja) | Ｐｃｐレセプター・リガンドおよびその用途 | |
| EP3270920B1 (en) | Organic compounds | |
| KR20160126988A (ko) | 아미노카보닐카바메이트 화합물 | |
| EP3339307A1 (en) | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions | |
| EP3418277B1 (en) | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | |
| Andersen et al. | 11C-labeling and preliminary evaluation of vortioxetine as a PET radioligand | |
| KR101679262B1 (ko) | 4-이소프로필크로만-3-올 화합물 | |
| EP2161998B1 (en) | Pyridine derivatives as NET/SERT modulators | |
| US10081600B2 (en) | 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof | |
| WO2015092720A1 (en) | Metabolites of sonidegib (lde225) | |
| EP3978497A1 (en) | Fused ring compound, preparation method therefor and use thereof | |
| AU2009301530A1 (en) | The 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof | |
| JP2010509250A (ja) | 新規な２−アミノ−ピリジン誘導体及びカリウムチャネルモジュレーターとしてのその使用 | |
| JP2010509249A (ja) | 新規な４−アミノ−ピリジン誘導体及びカリウムチャネルモジュレーターとしてのその使用 | |
| US20250195699A1 (en) | Radiolabeled Mu Opioid Antagonist and Methods of Making and Using the Same | |
| EP4488267A1 (en) | Histamine h3 receptor antagonist and medical use thereof | |
| CN116963733A (zh) | 作为enpp1抑制剂的咪唑化合物 | |
| AU2021329920A9 (en) | Serotonin receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190319 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: T-6-6-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20241128 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: T-6-6-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260415 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260415 |